News | Myriad Genetics

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

Pipeline

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

Pipeline

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

Products

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

Products

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

Pipeline

Myriad Announces Research Collaboration with University of Leeds

Pipeline

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

Pipeline

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

Products

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Pipeline

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Products

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

Products

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

Pipeline

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

Pipeline

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

Pipeline

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

Pipeline